Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

reticulum cell sarcoma - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

reticulum cell sarcoma

MONDO:0009975

Also known as:histiocytic lymphomainterdigitating cell sarcomalarge-cell Lymphomas

Find Clinical TrialsTrials

Overview

An antiquated term that refers to a non-Hodgkin lymphoma composed of diffuse infiltrates of large, often anaplastic lymphocytes.

GeneticsAutosomal recessive

Treatments2 FDA approved

Clinical Trials15 registered · 6 recruiting

Clinical Presentation

Features include: Neoplasm and Sarcoma.

Organ System	Phenotype Count	Example Features
Neoplasm	1	Neoplasm

Explore clinical features

Diagnosis

Biomarker and diagnostic research for reticulum cell sarcoma has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for reticulum cell sarcoma, including CYCLOPHOSPHAMIDE INJECTION, SOLUTION (CYCLOPHOSPHAMIDE, approved 2023) and CYCLOPHOSPHAMIDE (FRINDOVYX, approved 2023).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

15 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE2, 7 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT01137643](https://clinicaltrials.gov/study/NCT01137643)

Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 9:11 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:267730

Orphanet

European rare disease database

Orphanet:86900

GARD

Genetic and Rare Diseases Info Center

GARD:16765

Questions for Your Care Team

→What are the benefits and potential side effects of CYCLOPHOSPHAMIDE for managing reticulum cell sarcoma?
→Should my partner and I meet with a genetic counselor to discuss carrier status and family planning?
→Are any of the 15 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Laboratory research	12	40%
Disease patterns and progression	6	20%
New treatment approaches	5	17%
Patient case studies	3	10%
Research summaries	2	7%
Testing and diagnosis research	1	3%
Clinical study results	1	3%

reticulum cell sarcoma

Overview

Clinical Presentation

Explore clinical features

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications